See more : InflaRx N.V. (IFRX) Income Statement Analysis – Financial Results
Complete financial analysis of Akero Therapeutics, Inc. (AKRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Akero Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rajthanee Hospital Public Company Limited (RJH.BK) Income Statement Analysis – Financial Results
- Post Holdings Partnering Corporation (PSPC-WT) Income Statement Analysis – Financial Results
- Shanxi Zhendong Pharmaceutical Co.,Ltd (300158.SZ) Income Statement Analysis – Financial Results
- Sartorius Aktiengesellschaft (0NIQ.L) Income Statement Analysis – Financial Results
- Tai Shing Electronics Components Corporation (3426.TWO) Income Statement Analysis – Financial Results
Akero Therapeutics, Inc. (AKRO)
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 29.00K | 260.00K | 244.00K | 213.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -29.00K | -260.00K | -244.00K | -213.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 141.80M | 85.28M | 81.76M | 64.92M | 37.05M | 11.88M | 3.49M |
| General & Administrative | 31.07M | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M | 1.18M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -98.00K |
| SG&A | 31.07M | 29.87M | 19.13M | 15.24M | 8.61M | 1.90M | 1.08M |
| Other Expenses | 0.00 | 3.86M | 109.00K | 947.00K | 1.90M | -67.94M | 0.00 |
| Operating Expenses | 172.87M | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M | 4.56M |
| Cost & Expenses | 172.87M | 115.16M | 100.89M | 80.15M | 45.65M | 13.78M | 4.56M |
| Interest Income | 24.21M | 3.86M | 109.00K | 947.00K | 1.90M | 0.00 | 0.00 |
| Interest Expense | 3.10M | 739.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.00K | 260.00K | 244.00K | 213.00K | -104.00K | 13.78M | 4.98M |
| EBITDA | -148.63M | -111.03M | -100.53M | -78.99M | -45.65M | -68.46M | -232.36K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -172.87M | -115.16M | -100.89M | -80.15M | -45.65M | -13.78M | -4.56M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 21.11M | 3.12M | 109.00K | 947.00K | 1.90M | -67.94M | 0.00 |
| Income Before Tax | -151.76M | -112.03M | -100.78M | -79.21M | -43.76M | -81.71M | -4.56M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.12M | -41.00K | -17.00K | 24.00K | -68.10M | -4.98M |
| Net Income | -151.76M | -108.91M | -100.74M | -79.19M | -43.76M | -81.71M | -4.56M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.89 | -2.79 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| EPS Diluted | -2.89 | -2.79 | -2.89 | -2.52 | -2.90 | -3.85 | -0.16 |
| Weighted Avg Shares Out | 52.57M | 38.98M | 34.83M | 31.46M | 15.07M | 21.22M | 28.56M |
| Weighted Avg Shares Out (Dil) | 52.57M | 38.98M | 34.83M | 31.46M | 15.07M | 21.22M | 28.56M |
AKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
NEW ORLEANS, June 12, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO),...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO) and reminds investors of the June 25, 2024...
AKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) and...
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ:...
AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive...
AKRO INVESTOR NOTICE: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
SAN DIEGO, CA / ACCESSWIRE / June 11, 2024 / Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Akero Therapeutics, Inc. (NASDAQ:AKRO) common stock between September 13, 2022...
Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. (AKRO) - Contact Kessler Topaz Meltzer & Check, LLP
RADNOR, PA / ACCESSWIRE / June 11, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern...
Akero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the SYNCHRONY Outcomes study, a Phase...
AKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO) and...
Source: https://incomestatements.info
Category: Stock Reports